GlioCART GmbH

The company aims to develop, produce, and market CAR-T cell therapies against glioblastomas based on the licensed IP of the University of Basel and other licensed and self-developed cell therapies, which are based on the same approaches as those of the already licensed IP of the University of Basel. The company can establish branches both domestically and abroad and participate in other enterprises both domestically and abroad. The company can conduct all business activities that are related to its purpose and suitable to promote or facilitate the development of the enterprise. It can arrange financing for itself and third parties as well as provide guarantees and other securities.